Mission Statement, Vision, & Core Values (2026) of Jubilant Pharmova Limited.

Jubilant Pharmova Limited stands at the crossroads of global scale and focused innovation, operating across three integrated segments-Pharmaceuticals, Drug Discovery & Development Solutions, and Proprietary Novel Drugs-to serve regulated markets in over 85 countries with specialties ranging from radiopharmaceuticals and allergy therapies to contract manufacturing of sterile injectables and proprietary novel medicines; backed by USFDA‑approved facilities and a workforce of more than 5,500 professionals, the company is recognized as a "Partner of Choice" by leading global pharma firms and has demonstrated strong ESG credentials, scoring in the 94th percentile in the S&P Global ESG Indices CSA 2022 while pursuing sustainability through energy reduction and renewable adoption, and financially targets a return on invested capital at least 10 percentage points above its cost of capital as it strives to be among the top 10 most admired employers and continue creating growth opportunities in its strategic businesses.

Jubilant Pharmova Limited (JUBLPHARMA.NS) - Intro

• Geographic reach: presence in 85+ countries, servicing North America, Europe and emerging markets.
• Workforce: more than 5,500 employees across R&D, manufacturing and commercial functions.
• Regulatory & quality: multiple USFDA‑approved plants and global GMP compliance.
• ESG recognition: 94th percentile in the S&P Global ESG Indices CSA 2022.

• Pharmaceuticals: contract manufacturing (sterile injectables, non‑sterile formulations), radiopharma manufacturing and allergy therapeutics.
• Drug Discovery & Development Solutions: integrated R&D services, discovery chemistry, biologics support and CRO/CDMO capabilities.
• Proprietary Novel Drugs: internally developed clinical candidates and radiotheranostics pipeline assets.

• Scale sterile and radiopharma manufacturing to meet growing demand from regulated markets and to deepen CDMO relationships.
• Advance proprietary novel drugs and radiotheranostics through clinical development to capture higher‑margin specialty opportunities.
• Expand DDDS capabilities (discovery to clinical supply) to become a preferred partner for integrated R&D outsourcing.
• Maintain high regulatory compliance and quality standards to protect market access in regulated geographies.
• Embed sustainability across operations-reducing emissions, improving resource efficiency and enhancing social impact.

• Positioning: a diversified pharma platform with manufacturing scale, integrated R&D services and an early‑stage proprietary pipeline.
• Partnership appeal: recognized as a "Partner of Choice" by global pharma companies for contract development and manufacturing.
• ESG track record: strong third‑party recognition (S&P Global CSA 2022), supporting longer‑term license‑to‑operate and investor interest.

Jubilant Pharmova Limited (JUBLPHARMA.NS): Overview

• Mission: Deliver value to customers via innovative, cost‑effective products and solutions; enhance shareholder value through sales growth, cost discipline and prudent capital allocation.
• Environmental commitment: Manufacture with optimized resource utilization to reduce emissions, waste and water usage; prioritize energy efficiency and renewable sources.
• Stakeholder value: Drive excellence, operational efficiency, profitable growth and continuous innovation across specialty pharma, contract development & manufacturing (CDMO) and life‑science ingredients.
• People ambition: Aspire to be among the top 10 most admired companies to work for by focusing on employee engagement, training, safety and inclusive culture.
• Financial target: Seek a return on invested capital (ROIC) at least 10 percentage points higher than the company's cost of capital.
• Carbon & energy goals: Reduce carbon footprint through energy‑consumption reduction programs and increased use of renewables.

• R&D and product innovation pipelines focused on high‑value specialty molecules and differentiated formulations.
• Capacity optimization and brownfield/greenfield investments prioritized by expected ROIC and strategic fit.
• Process improvements, lean manufacturing and digitalization to lower per‑unit cost and improve throughput.
• Sustainability programs: energy efficiency projects, onsite renewable generation, waste minimization and water recycling.
• Human capital programs: targeted training, safety systems, diversity & inclusion and performance‑linked incentives.

• Financial KPIs: Revenue growth, segmental EBITDA, ROIC vs weighted average cost of capital (WACC), free cash flow and return on equity.
• Operational KPIs: Capacity utilization, yield improvements, cost per kg/unit, time‑to‑market for new products.
• Sustainability KPIs: Energy use intensity, % renewable energy, Scope 1 & 2 emissions, waste‑to‑landfill, water intensity.
• People KPIs: Employee engagement scores, LTIFR (lost time injury frequency rate), training hours per employee and attrition rates.

Jubilant Pharmova Limited (JUBLPHARMA.NS) - Mission Statement

• Attain and sustain global leadership positions in chosen business verticals through focused investments, capacity expansion, and innovation.
• Create continuous growth opportunities across strategic businesses via new product introductions, geographic expansion, and partnerships.
• Build an organization that ranks among the top 10 most admired employers by strengthening employee engagement, learning, and well‑being programs.
• Deliver superior financial returns by targeting a return on invested capital (ROIC) at least 10 percentage points above the company's cost of capital.
• Reduce carbon footprint through energy‑efficiency measures and increased use of renewable energy across manufacturing sites.
• Optimize resource utilization in manufacturing to minimize environmental impact (water, waste, raw materials) and improve circularity.

• Capital allocation framework: prioritize projects expected to meet the ROIC premium (cost of capital + 10 pp) and divest non‑core assets that do not meet return thresholds.
• Sustainability initiatives: energy efficiency retrofits, onsite solar and renewable procurement, process-water recycling, and waste-minimization programs tied to site KPIs.
• People strategy: structured employee engagement surveys, leadership development, diversity & inclusion initiatives, and competitive total‑reward programs to reach top‑10 employer aspiration.
• Growth levers: targeted R&D investments, capacity expansions in high‑growth segments, selective M&A, and commercial expansion into priority markets.

Jubilant Pharmova Limited (JUBLPHARMA.NS) - Vision Statement

• Integrity: Business decisions anchored in transparency, compliance and ethical conduct across global operations.
• Innovation: Continuous investment in R&D to advance differentiated drug-delivery systems, CDMO services, and radiopharmaceuticals.
• Excellence: Commitment to world-class manufacturing standards (GMP), quality assurance and regulatory compliance.
• Collaboration: Cross-functional teamwork across R&D, manufacturing, commercial and strategic partners to accelerate time-to-market.
• Accountability: Clear ownership of outcomes, measurable KPIs and rigorous governance to deliver on promises.
• Sustainability: Environmental and social initiatives aimed at reducing footprint and enhancing community health and safety.

The company's vision is operationalized through measurable targets across financial performance, R&D intensity, manufacturing quality and sustainability metrics. Recent public disclosures and investor communications highlight a multi-pronged strategy: expand high-margin CDMO and radiopharma offerings, strengthen specialty pharma and API portfolios, and scale contract manufacturing and drug-delivery solutions.

Core values translate into operational practices and KPIs across functions:

• Integrity: Mandatory compliance training for employees; third-party audits and transparent financial reporting.
• Innovation: Dedicated R&D centers; collaborations with academia and biotech partners to shorten development cycles.
• Excellence: Certifications and regulatory approvals (GMP, ISO) for key plants; continual quality audits.
• Collaboration: Cross-border teams for CDMO projects and strategic alliances with global pharma companies.
• Accountability: Performance-linked metrics for project delivery, quality incidents and financial targets.
• Sustainability: Initiatives targeting water recycling, renewable energy adoption and community health programs.

Strategic imperatives mapped to the vision and values include:

• Scale high-return segments (CDMO, radiopharma) while optimizing lower-margin legacy portfolios.
• Increase R&D productivity and accelerate commercialization of specialty offerings.
• Strengthen balance sheet through disciplined cash flow management and prioritized capex.
• Embed ESG across decision-making to meet stakeholder expectations and regulatory trends.

For investors and stakeholders seeking a deeper financial analysis and recent performance metrics, see: Breaking Down Jubilant Pharmova Limited Financial Health: Key Insights for Investors